FDA Inspection 1293950 — Albert Wiegman
The FDA completed an inspection of Albert Wiegman on Nov 13, 2025 in Amsterdam. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 13, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Amsterdam (Netherlands)
Additional Details
Clinical Investigator (CI)